PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,342,164
|
tyramid signal amplif immunofluoresc stain zbp depend phosphoryl ripk mlkl hsv infect human cell kinas receptor interact serinethreonin protein kinas ripk substrat mix lineag kinas domain like mlkl critic regul necroptosi inflammatori form cell death import antivir function autophosphoryl ripk induc phosphoryl activ pore form execution protein necroptosi mlkl traffick oligomer phosphoryl mlkl cell membran result cell lysi characterist necroptot cell death nucleic acid sensor zbp activ bind left hand z form doubl strand rna z rna infect rna dna virus zbp activ restrict virus infect induc regul cell death includ necroptosi infect host cell immunofluoresc microscopi permit visual differ signal step downstream zbp mediat necroptosi per cell basi howev sensit standard fluoresc microscopi use current commerci avail phospho specif antibodi human ripk mlkl preclud reproduc imag marker describ optim stain procedur serin phosphoryl ripk mlkl human ht cell infect herp simplex virus hsv inclus tyramid signal amplif tsa step immunofluoresc stain protocol allow specif detect phosphoryl ripk moreov tsa great increas sensit detect phosphoryl mlkl togeth method enabl visual two critic signal event induct zbp induc necroptosi
|
D018259;D006566;D006561
|
T005;T047
|
36,342,156
|
gene digit circuit base crispr cas system anti crispr protein synthet gene boolean gate digit circuit broad rang applic medic diagnost environment care discoveri crispr cas system natur inhibitor anti crispr protein acr provid new tool design implement vivo gene digit circuit describ protocol follow idea design build test learn biolog engin cycl make use dcasdcasa togeth correspond acr establish small transcript network behav like boolean gate saccharomyc cerevisia result point properti dcasdcasa transcript factor particular achiev maxim activ gene express dspcas need interact engin scaffold rna collect multipl copi vp activ domain ad contrast dcasa shall fuse c terminus strong vp p rta vpr ad furthermor activ cas protein enhanc increas amount sgrnacrrna cell articl also explain build boolean gate base crispr dcas acr interact acriia fuse hormon bind domain human estrogen receptor core gate respons estradiol wherea acrva synthes induc gal promot permit mimic yes gate galactos input latter circuit acrva togeth dlbcasa show best logic behavior
|
D064113;D053263
|
T040;T044
|
36,342,153
|
integr spreadsheet nutrit analysi popul diet survey challeng calcul nutrient intak popul diet survey exist nutrit analysi softwar general orient toward analyz intak individu may allow user input easili modifi food composit data use analysi drawback problemat low middl incom countri set numer softwar assist dietari assess platform conduct onboard nutrit analysi appropri use larg survey often similar limit restrict user specif assess modal paper present multifunct system integr spreadsheet nutrit analysi popul diet survey isnapd provid solut situat data collect adequ analyz exist softwar protocol involv suppli system fulli customiz data food composit food group classif food intak food intak gday may enter direct calcul base user suppli intak frequenc either standard variabl serv size follow data entri user modifi set simpl pre popul formula match structur input data system appli formula calcul nutrient food group intak contribut food group nutrient intak member survey popul flexibl isnapd system allow accommod global divers food consum analyz quantit semiquantit nonquantit food consumpt data collect use prospect retrospect assess method employ differ refer period portion size estim method date system appli publish ongo analys h recal diet record food frequenc disaggreg household consumpt data popul survey china ethiopia india mongolia thailand multi countri analysi sub saharan african countri
|
D004032;D004435
|
T033;T168;T040;T038
|
36,342,149
|
use hyperbar oxygen improv radiosensit human u glioma cell aim studi explor use hyperbar oxygen enhanc radiosensit human glioma cell sub cultur u human glioma cell random divid four group untreat control group cell treat hyperbar oxygen hbo cell treat x ray irradi x ray cell treat hbo x ray cell morpholog cell prolifer activ cell cycl distribut apoptosi observ group evalu role hbo improv radiosensit glioma cell increas x ray dose gy gy gy gy gy surviv fraction sf glioma cell gradual decreas signific lower sf observ cell treat hbo x ray togeth x ray group dose p prolifer inhibit signific higher hbo combin x ray group x ray group dose p u cell line percentag gm phase cell signific higher hbo combin x ray gy group hbo group control group x ray gy group p u cell apoptosi signific higher hbo combin x ray gy group hbo group x ray gy group control group p conclud hbo enhanc prolifer inhibit apoptosi glioma u cell block glioma cell gm phase improv radiosensit u glioma cell
|
D006931;D005910;D011838
|
T061;T121;T039;T191
|
36,342,145
|
neuromuscular ultrasound median nerv carpal tunnel use neuromuscular ultrasound great enhanc evalu carpal tunnel syndrom adjunct diagnost tool provid dynam structur inform median nerv surround anatomi neuromuscular ultrasound aid diagnost accuraci use electrodiagnost test offer etiolog inform non invas painless cost effect radiat free imag technolog easili carri bedsid immedi interpret neuromuscular ultrasound limit subject need train experi affect interpret result articl describ basic practic guid visual median nerv use neuromuscular ultrasound step step manner aid evalu carpal tunnel syndrom even though use ultrasound assess median nerv entrap long establish recogn standard protocol present protocol aim provid clear concis instruct describ standard techniqu visual median nerv diagnost ultrasound
|
D008475;D002349
|
T023;T047
|
36,342,137
|
assess mitochondri health cancer associ fibroblast isol multicellular lung tumor spheroid cancer associ fibroblast caf among abund stromal cell present tumor microenviron facilit tumor growth progress complex within tumor microenviron includ tumor secretom low grade inflamm hypoxia redox imbal foster heterotyp interact allow transform inact resid fibroblast becom activ caf caf metabol distinguish normal fibroblast nfs glycolyt activ produc higher level reactiv oxygen speci ros overexpress lactat export mct lead open mitochondri permeabl transit pore mptp method describ analyz mitochondri health activ caf isol multicellular tumor spheroid compris human lung adenocarcinoma cell human monocyt thp human lung fibroblast cell mrc tumor spheroid disintegr differ time interv magnet activ cell sort caf isol mitochondri membran potenti caf assess use jc dye ros product dichlorodihydrofluorescein diacet dcfda stain enzym activ isol caf analyz mitochondri health isol caf provid better understand revers warburg effect also appli studi consequ caf mitochondri chang metabol flux correspond regulatori mechan lung cancer heterogen thus present studi advoc understand tumor stroma interact mitochondri health would provid platform check mitochondri specif drug candid efficaci caf potenti therapeut tumor microenviron therebi prevent caf involv lung cancer progress
|
D000072645;D008175;D000077192
|
T191;T025
|
36,342,136
|
hybrid cell analysi system assess structur contractil chang human ipsc deriv cardiomyocyt preclin cardiac risk evalu cardiac contractil assess immens import develop new therapeut safe transit clinic stage human induc pluripot stem cell deriv cardiomyocyt hipsc cms hold promis serv human relev model preclin phase drug discoveri safeti pharmacolog matur still controversi scientif communiti constant develop present hybrid contractil impedanceextracellular field potenti efp technolog ad signific pro matur featur industri standard well platform impedanceefp system monitor cellular function real time besid beat rate contractil cell electr imped spectroscopi readout detect compound induc morpholog chang like cell densiti integr cellular monolay compon hybrid cell analysi system cell cultur bio compliant membran mimic mechan environ real heart tissu physiolog environ support matur hipsc cms vitro lead adult like contractil respons includ posit inotrop effect treatment isoproterenol bay k omecamtiv mecarbil paramet amplitud contract forc mnmm beat durat also reveal downstream effect compound influenc electrophysiolog properti calcium handl hybrid system provid ideal tool holist cell analysi allow preclin cardiac risk assess beyond current perspect human relev cell base assay
|
D057026
|
T025
|
36,342,133
|
collect trust game onlin group adapt trust game base honeycomb paradigm need understand trust group holist led surg new approach measur collect trust howev construct often fulli captur emerg qualiti avail research method paper collect trust game ctg present comput base multi agent trust game base honeycomb paradigm enabl research assess emerg collect trust ctg build previous research interperson trust adapt wide known trust game group set honeycomb paradigm particip take role either investor truste role play group initi investor truste endow sum money investor need decid much endow want send truste communic tendenc well final decis move back forth playfield display possibl invest amount end decis time amount investor agre upon multipli sent truste truste communic much invest want return investor move playfield procedur repeat multipl round collect trust emerg share construct repeat interact procedur ctg provid opportun follow emerg collect trust real time record movement data ctg high customiz specif research question run onlin experi littl low cost equip paper show ctg combin rich group interact data high intern valid time effect econom game
|
D035502;D018910
|
T073;T054
|
36,342,132
|
determin mechan properti flexibl connector use insul concret wall panel document contain recommend perform non standard doubl shear test suitabl continu discret insul concret sandwich wall panel icswp standard test exist sever iter similar test perform literatur vari degre success test literatur rare ever describ detail discuss length respect test data analysi safeti procedur test specimen configur recommend herein variat discuss import mechan properti identifi load versus displac data extract detail use test data design determin stiff connector briefli demonstr show icswp deflect crack behavior may calcul strength behavior panel may determin use full load versus displac curv maximum connector strength shortcom unknown acknowledg signific futur work delin
|
D013314
|
T070
|
36,342,129
|
investig stress relax failur respons trachea biomechan properti trachea direct affect airflow contribut biolog function respiratori system understand properti critic understand injuri mechan tissu protocol describ experiment approach studi stress relax behavior porcin trachea pre stretch strain follow mechan tensil load failur studi provid detail experiment design data acquisit analys preliminari result porcin trachea biomechan test use detail step provid protocol data analysi matlab code futur studi investig time depend viscoelast behavior trachea tissu critic understand biomechan respons physiolog patholog traumat condit furthermor depth studi biomechan behavior trachea critic aid improv design relat medic devic endotrach implant wide use surgeri
|
D014132;D012143
|
T039;T023;T070;T042
|
36,342,128
|
full field optic coher microscopi histolog like analysi stromal featur corneal graft qualiti donor corneal stroma make total corneal thick like one main major limit factor success deep anterior lamellar penetr keratoplasti surgic procedur involv replac part diseas corneal layer respect donat tissu graft taken recent deceas individu howev mean evalu stromal qualiti corneal graft eye bank limit lack capabl high resolut quantit assess diseas indic full field optic coher microscopi ff ocm permit high resolut imag fresh fix ex vivo biolog tissu sampl non invas techniqu well suit donor cornea assess describ method qualit quantit analysi corneal stroma use ff ocm protocol success appli normal donor cornea patholog corneal button use identifi healthi patholog featur macroscop microscop level therebi facilit detect stromal disord could compromis outcom keratoplasti improv graft qualiti control protocol potenti result better select reject donor tissu henc decreas graft failur
|
D016039
|
T061
|
36,342,072
|
concern perceiv clinic measur level halitosi differ type self report halitosi complaint includ one feel one breath smell bad one feel one bad breath attitud other other point presenc bad breath result previous studi compar object subject measur halitosi inconsist studi use gas chromatographi gc measur halitosi larg sampl studi aim examin object measur halitosi level base reason individu concern halitosi includ patient visit halitosi clinic univers dental hospit halitosi assess use gc self administ questionnair oral examin level volatil sulphur compound vscs h ch sh ch set object measur halitosi patient group base answer made concern bad breath group self perceiv attitud other told other reason univari multivari linear regress analys perform examin factor associ vscs object halitosi level age sex oral health status smoke drink breakfast habit use confound patient answer told other n show highest vscs individu whose halitosi point other higher object measur halitosi level concern attitud other perceiv halitosi lower object measur halitosi level result suggest object level halitosi differ basi reason under individu concern bad breath categor halitosi complaint compar object halitosi level may help reduc anxieti concern halitosi confirm need intervent object halitosi
|
D006209
|
T184
|
36,342,018
|
biospher emerg call scientist chang tactic current econom polit structur increas devast impact earth climat ecosystem face biospher emerg catastroph consequ human natur world depend life scientist includ biologist medic scientist psychologist public health expert crucial role document impact emerg fail drive govern take action order prevent situat get wors member movement scientist rebellion call life scientist embrac advocaci activ hallmark academia order highlight urgenc necess system chang across societi particular emphasis need scientist engag nonviol civil resist form public engag proven high effect social struggl throughout histori
|
D017753;D011634
|
T070;T091;T082
|
36,341,994
|
inhibitori effect infliximab orthodont tooth movement male rat studi aim investig effect infliximab orthodont tooth movement rat
|
D014087;D014409
|
T061;T129;T116
|
36,341,991
|
compar contractil properti within integr group muscl abdomin wall abdomin wall extern obliqu eo intern obliqu io rectus abdomini ra transvers abdomini tra function anatom integr group muscl passiv mechan properti individu abdomin muscl studi previous contractil properti yet describ muscl sampl taken eo io ra tra spragu dawley rat singl muscl fibr isol sampl chemic permeabil test ca pca bath determin contractil properti specif forc activ modulus unload shorten veloc rate forc redevelop myosin heavi chain mhc isoform identifi gel electrophoresi determin fibr type test fibr well larger bundl fibr type fibr two type iia fibr test therefor type iix iib fibr combin statist analysi signific differ muscl specif forc activ modulus unload shorten veloc p gt rate forc redevelop statist signific p tra greater eo suggest faster cross bridg transit low high forc generat state tra function signific differ unclear need studi
|
D034861
|
T023
|
36,341,990
|
thenumb stepsneededfor ucm gait analysisdiff healthi stroke basi uncontrol manifold ucm approach variabl among repetit motor task thus reliabl result might influenc number trial studi estim number step need ucm analysi stroke gait healthi subject twenti five volunt particip sixteen stroke group age year ten hemiparesi right nine healthi group age year appli ucm analysi lower limb singl support phase ssp center mass sagitt plane task variabl ankl knee hip joint angl element variabl result obtain step use refer compar obtain separ step mean valu curv along ssp compar set step volunt calcul pearson correl step curv obtain number step result indic number step necessari perform ucm analysi stroke gait larger necessari healthi condit synergi index less sensit number step ucm compon vucm vort analysi ucm time requir signific number step mean valu
|
D005684;D020521
|
T033;T047
|
36,341,892
|
investig intervent method base differ lead role famili regard child road safeti educ experiment studi children vulner traffic injuri due low hazard percept previous studi indic parent children potenti lead role safeti educ within famili howev effect differ lead role parent children hazard percept children yet reveal interact educ children lead role could also import mean enhanc children road safeti fill gap base constructiv theori feynman learn method studi propos two method enhanc children hazard percept base differ lead role famili regard child road safeti educ investig effect intervent method thirti set parent children particip experi divid three group children receiv one three differ road safeti intervent constructiv intervent parent guidanc intervent children feynman learn intervent compar constructiv intervent hazard percept children receiv road safeti educ within famili signific improv children sensit potenti traffic hazard factor present better visual search pattern compar analysi show two educ intervent base differ lead role famili regard child road safeti educ ident respect effect children feynman learn intervent signific effect parent guidanc intervent find studi provid insight inform safeti educ research govern educ famili children
|
D000063;D010290
|
T099;T037;T102;T067
|
36,341,889
|
load bear capac pressabl lithium disil appli ultra thin occlus veneer molar aim investig load bear capac differ pressabl lithium disil cement occlus veneer molar
|
D002516;D008094
|
T121;T196;T073
|
36,341,886
|
radiosynthesi f fluoroarachidon acid pet mr imag biolog evalu apo tr mice dysreglul brain arachidon acid aa metabol involv chronic inflamm influenc apolipoprotein e apo genotyp strongest genet risk factor late onset alzheim diseas ad visual aa uptak distribut brain offer insight neuroinflamm ad pathogenesi present novel synthesi radiosynthesi f fluoroarachidon acid f faa pet imag use converg rout one pot singl purif radiolabel procedur demonstr brain uptak human apo target replac apo tr mice examin p phosphoryl astrocyt found fluorin aa posit signific alter biochem role cell brain incorpor coeffici k f faa estim via multipl method use imag deriv input function right ventricl heart proxi arteri input function brain tracer concentr assess dynam pet mr imag new synthet approach facilit practic f faa product allow translat clinic use make investig dysregul lipid metabol feasibl studi neurodegen diseas
|
D053327;D000544
|
T047;T116;T048
|
36,341,786
|
inflammag bodi composit new insight diabet hypertens elder men age relat chang bodi physiolog respons play critic role system arteri hypertens sah type diabet mellitus tdm sah tdm clinic silent low grade inflamm common risk factor inflamm relev element excess fatti tissu scenario littl known inflammatori marker interact therefor work evalu interplay among anthropometr biochem inflammatori marker elder sah tdm men age year old sah tdm classifi bodi mass index bmi eutroph elder ee individu overweight elder oe individu bodi composit analysi perform use bioimped blood sampl collect perform inflammatori biochem evalu cytokin il il ifn tnf il evalu elisa triglycerid total fraction cholesterol glucos measur spectrophotometri overweight elder men higher glycem index increas anthropometr marker well higher mean pro inflammatori cytokin analyz il il ifn tnf comparison eutroph elder counterpart howev decreas il anti inflammatori cytokin il il ratio compar eutroph elder counterpart although overweight elder men worsen inflammatori paramet magnitud correl anthropometr biochem paramet becom less evid bayesian network highlight eutroph elder il tnf cytokin associ interact interact occur biochem paramet worth highlight role ifn overweight elder men cytokin influenc il tnf product contribut inflammatori profil exacerb group
|
D003924;D006973
|
T047
|
36,341,785
|
comparison clinic characterist outcom measur pcr posit pcr negat patient diagnos covid analys focus older adult definit diagnosi covid reli pcr confirm virus sensit techniqu limit clinician go clinic diagnosi covid select case aim compar pcr posit pcr negat patient diagnos covid specif focus older adult
|
D000086382;D011014
|
T047;T050;T067
|
36,341,755
|
develop character activ packag nanofib mat base gelatinsodium algin contain probiot microorgan improv shelf life safeti qualiti silver carp fillet current studi aim incorpor lactobacillus acidophilus limosilactobacillus reuteri lacticaseibacillus casei lacticaseibacillus rhamnosus log cfuml gelatinsodium algin nanofib via electrospin process order investig influenc fabric mat growth food relat pathogen bacteria shelf life extens refriger silver carp fillet two week period strain load nanofib exhibit lower water vapor permeabl swell index moistur content tensil strength straight nanofib p l rhamnosus log cfug probiot mat signific delay growth vibrio parahaemolyticus salmonella typhimurium staphylococcus aureus listeria monocytogen silver carp fillet comparison unpackag sampl p moreov design nanofib improv bacteri chemic sensori properti treat sampl comparison unpackag sampl throughout studi period find indic gelatinsodium algin nanofib suitabl platform protect live probiot present altern procedur retard growth food born pathogen extend shelf life fresh carp fillet refriger storag condit
|
D002347;D057139;D008089;D019936
|
T007;T073;T013
|
36,341,753
|
intens blood pressur control endovascular thrombectomi acut ischaem stroke enchantedmt multicentr open label blind endpoint randomis control trial optimum systol blood pressur endovascular thrombectomi acut ischaem stroke uncertain aim compar safeti efficaci blood pressur lower treatment accord intens versus less intens treatment target patient elev blood pressur reperfus endovascular treatment
|
D002545;D020521;D000083242
|
T047;T046
|
36,341,748
|
earli intervent obsess compuls disord theori practic obsess compuls disord ocd frequent often disabl yet correct diagnosi appropri treatment implement usual delay undesir consequ paper review rational earli intervent ocd provid recommend earli intervent servic two scenario discuss ie subclin prodrom obsess compuls symptom oc full blown ocd although typic patient ocd report long histori subclin oc longitudin studi suggest individu oc communiti convert full blown ocd thus research risk phenotyp ocd incorpor differ risk factor eg polygen risk score bad need specif scenario prevent treatment cheap well toler high scalabl eg lifestyl intervent major interest hand increas evid suggest ocd progress disord sever durat ill associ biolog chang increas clinic complex includ greater number physic psychiatr comorbid increas famili accommod wors treatment respons therefor prompt identif earli treatment implement full blown ocd also critic ethic clinic therapeut reason base exist find argu regardless focus subclin oc clinic ocd earli intervent servic need target childhood age group addit deliv well establish treatment peopl full blown ocd earli ill earli intervent servic also need provid psychoeduc patient famili teacher
|
D009771
|
T048
|
36,341,747
|
accept feasibl measur prolong grief disord symptom daili life use experi sampl methodolog current grief research domin cross section studi assess prolong grief disord pgd symptom retrospect examin grief daili life use experi sampl methodolog esm may advanc field lack esm research pgd evalu accept feasibl assess pgd symptom daili life bereav peopl
|
D001601
|
T041
|
36,341,746
|
print biocompat elastom model muscl regener volumetr muscl loss volumetr muscl loss vml injuri due trauma tumor ablat degen muscl diseas debilit current limit option self repair advanc print allow rapid fabric biocompat scaffold design pattern howev materi chosen often stiff brittl optim muscl tissu engin studi util photopolymeriz biocompat elastom poli glycerol sebac acryl pgsa develop vitro model muscl regener prolifer acellular scaffold vml injuri mechan properti scaffold tune control light intens print process match specif tension skelet muscl effect geometr channel size biolog decellular muscl extracellular matrix decm cue muscl progenitor cell infiltr prolifer organ matur evalu vitro use near infrar fluoresc protein irfp transfect cell line assess cell scaffold larger channel size decm coat found enhanc cell prolifer matur discern effect cell align observ addit pilot experi carri evalu regen capac scaffold vivo vml injuri overal platform demonstr simpl model studi muscl progenitor recruit differenti acellular scaffold vml repair
|
D020724;D009135
|
T047;T122;T073;T109
|
36,341,745
|
bone surfac mimick pdms membran stimul osteoblast calcif bone matrix cellular microenviron play crucial role cell behavior addit biochem cue present microenviron biophys biomechan properti surfac impact cellular function eventu cellular fate effect surfac topographi cell behavior studi extens literatur howev studi often tri replic topograph featur tissu surfac use techniqu chemic etch photolithographi electrospin may result loss crucial micro nano featur tissu surfac bone studi investig topograph effect bone surfac transfer surfac featur onto polydimethylsiloxan pdms membran use soft lithographi bovin femur result shown major featur bone surfac success transfer onto pdms use soft lithographi osteoblast prolifer calcif bone matrix signific increas along osteoblast specif differenti matur marker osteocalcin osc osterix osx collagen type alpha chain cola alkalin phosphatas alp bone surfac mimick bsm pdms membran addit unidirect align osteoblast cell compar plain pdms surfac present bone surfac mimick method provid versatil nativ like platform investig intracellular pathway regard osteoblast growth differenti
|
D001857;D010006
|
T025;T024
|
36,341,744
|
amniot membran extract enrich hydrogel augment therapeut effect menstrual blood deriv stromal cell rat model intrauterin adhes previous demonstr transplant menstrual blood deriv stromal cell mensc safe effect therapi treat intrauterin adhes iua howev improv colon therapeut effici mensc still need full clinic applic establish amniot membran extract ame enrich rgd hydrogel evalu therapeut effect adjuv combin mensc transplant iua rat model result indic ame promot prolifer secret mensc vitro regul express apoptosi suppress gene bcl regul express apoptosi relat gene caspas caspas ame enrich hydrogel biocompat improv surviv mensc vitro vivo also promot retent mensc iua uterus augment effect mensc improv uterus morpholog endometri prolifer endometri recept fibrosi suppress addit co transplant mensc ame enrich hydrogel mark regul express inflamm relat gene il tgf regul ilifn ratio iua endometrium improv express cell prolifer relat antigen gland regener relat marker leucin rich repeat contain g protein coupl receptor lgr angiogenesi relat marker platelet endotheli cell adhes molecul pecam endometri recept relat gene itg itg studi suggest ame mensc synergist effect co transplant mensc ame enrich hydrogel provid promis approach stem cell base iua treatment
|
D000650;D014591
|
T018;T047
|
36,341,743
|
multi function nanofilm capabl angiogenesi near infrar trigger anti bacteri activ inflammatori regul infect wound heal chronic infect wound heal critic challeng clinic practic owe involv multipl physiolog process includ bacteria relat inflammatori regul angiogenesi therefor multi function strategi synergist anti bacteri anti inflammatori pro angiogen effect develop owe biomimet structur featur control deliveri activ agent electrospun nanofilm promis biomateri treatment skin defect studi fabric multi function nanofilm pro angiogen anti bacteri anti inflammatori capac first strontium sr ion incorpor poli l lactic co caprolacton plcl nanofilm subsequ polydopamin pda zinc oxid zno decor onto surfac sr load plcl nanofilm prepar znopda plcl sr nanofilm vitro result show znopda plcl sr nanofilm biocompat exhibit angiogen activ signific inhibit growth staphylococcus aureus escherichia coli upon near infrar light irradi furthermor znopda plcl sr nanofilm found drive transform macrophag phenotyp vivo result valid znopda plcl sr nanofilm exhibit pro angiogen anti bacteri activ regul inflamm acceler wound heal rat model bacteria infect skin defect conclus success develop multi function biomateri pro angiogen anti bacteri anti inflammatori capac treat chronic infect wound
|
D015034
|
T121;T197
|
36,341,741
|
biosynthesi character biomed potenti arthrospira indica sosa mediat senp use aqueous cyanobacteri extract selenium nanoparticl senp synthesi consid green cost effect eco friend technolog advanc physic chemic method current studi aqueous extract arthrospira indica sosa use reduc stabil agent green synthesi senp uv visibl absorpt spectroscopi fourier transform infrar ft ir spectroscopi x ray diffract raman spectroscopi atom forc microscopi afm scan electron microscopi energi dispers x ray spectroscopi sem edx transmiss electron microscopi tem perform character biosynthes senp gas chromatographi mass spectrometri gc ms also perform know composit cyanobacteri extract sem tem afm show averag size senp nm nm nm respect ft ir analysi demonstr presenc function group senp act stabil agent xrd pattern raman spectroscopi show amorph natur senp synthes senp show signific antioxid activ dpph frap sor abt assay senp show good anti microbi activ staphylococcus aureus escherichia coli candida albican candida glabrata candida tropicali good anti cancer activ mtt assay trypan assay flow cytometri analysi mcf siha sw cell line non toxic senp normal cell line hek addit properti affirm potenti bio compat nanomateri
|
D012643;D000458
|
T123;T196;T121;T007
|
36,341,740
|
thiol michael addit base conjug glutathion activ releas glutathion gsh level long recogn valuabl tumor biomark gsh mediat activ releas system extens develop cancer diagnosi treatment main focus disulfid base conjug report new thiol michael addit base gsh respons conjug tc consist uniqu tricycl structur contain unsatur keton respons group conjug easili synthes show good select glutathion certain stabil camptothecin deliveri experi tc show improv anti tumor abil cell tumor bear mice tc could use develop antibodi small molecul conjug drug
|
D013438;D005978
|
T123;T121;T116;T109;T034
|
36,341,739
|
multifacet role peptid alway near infrar fluoresc probe tumor imag tumor target near infrar nir fluoresc imag use nir fluoresc probe attract extens attent field tumor imag becom attract strategi earli cancer diagnosi surgic guidanc past decad especi due high affin low toxic peptid base nir fluoresc probe play import role field tumor target imag therapi extens attempt made develop set nontox efficaci alway peptid base nir fluoresc probe review give comprehens analysi alway peptid base nir fluoresc probe tumor target past year highlight design strategi chemic synthesi therapeut applic spectroscop pharmacolog character well multifacet role peptid comprehens understand tumor target alway peptid base nir fluoresc probe increas knowledg cancer diagnosi benefit clinic cancer therapeut
|
D005456;D009369
|
T191;T130
|
36,341,679
|
pharmacolog inhibit acetyltransferas tip mitig myocardi infarct injuri pharmacolog strategi target factor pro apoptot anti prolif function cardiomyocyt cms may use treatment ischem heart diseas one multifunct candid drug target acetyltransferas tip known acetyl histon non histon protein target shown cancer cell promot apoptosi initi dna damag respons therebi limit cellular expans use murin model recent publish find demonstr cm specif disrupt kat gene encod tip mark protect damag effect myocardi infarct mi experi describ lieu genet target administ th experiment drug design specif inhibit acetyltransferas domain tip report similar effect disrupt kat gene daili system administr th begin day induct mi continu week week timelin result improv systol function reduc apoptosi scar increas activ cm cell cycl effect accompani reduc express gene promot apoptosi inhibit cell cycl reduc level cms exhibit phosphoryl atm result support possibl drug inhibit acetyltransferas activ tip may use agent treatment ischem heart diseas
|
D051548;D009203
|
T047;T126;T116
|
36,341,584
|
first sar cov vaccin booster influenza vaccin risk assess covid hospitalis death influenza sar cov virus share common respiratori symptomatolog transmiss mode covid influenza r overlap first epidem wave autumn winter influenza epidem delay onset compar pre covid year lower incid rate pre pandem period sar cov influenza vaccin campaign overlap
|
D000086382;D007252;D007251
|
T129;T121;T067;T109;T047
|
36,341,583
|
descript excess overal caus specif mortal agenc health protect metropolitan area milan lombardi region northern itali result sar cov pandem generalis mortal excess record howev mortal covid fulli explain observ excess analysi caus specif mortal could contribut estim direct indirect effect sar cov outbreak monitor mortal trend
|
D000086382;D009369
|
T047;T191;T067
|
36,341,568
|
ultrafast simul larg scale neocort microcircuitri biophys realist neuron understand activ mammalian brain requir integr knowledg circuit distinct scale rang ion channel gate circuit connectom comput model regular employ understand multipl paramet contribut synergist circuit behavior howev tradit model anatom biophys realist neuron comput demand especi scale model local circuit overcom limit train sever artifici neural network ann architectur model activ realist multicompartment cortic neuron identifi ann architectur accur predict subthreshold activ action potenti fire ann could correct general previous unobserv synapt input includ model contain nonlinear dendrit properti scale process time order magnitud faster compar tradit approach allow rapid paramet space map circuit model rett syndrom thus present novel ann approach allow rapid detail network experi use inexpens common avail comput resourc
|
D008959;D019579
|
T023;T170;T024
|
36,341,567
|
uncompl cours covid primari immunodefici patient report common variabl immunodefici patient coronavirus diseas covid affect million peopl worldwid clinic manifest rang asymptomat sever viral pneumonia cvid patient covid infect adequ studi studi cvid patient higher mortal rate although studi show cvid patient might uncompl covid infect describ case covid infect iranian cvid patient studi includ clinic manifest laboratori find treatment strategi patient mild diseas moder diseas sever diseas studi critic case death occur none patient six case infect two week receiv second dose sinopharm bibp covid vaccin mild moder diseas among patient remdesivir frequent prescrib medic accord studi patient present uncompl diseas cours
|
D017074;D000086382;D011024
|
T047;T067
|
36,341,566
|
cell receptor repertoir divers follow hematopoiet stem cell transplant immun reconstitut hematopoiet stem cell transplant hsct condit regimen appear promis treatment autoimmun diseas hematolog malign studi aim assess cell receptor tcr repertoir divers cd cell patient hematolog malign receiv allogen autolog hsct divers tcr repertoir evalu patient hematolog malign four month hsct amino acid chang v famili evalu use spectratyp data present ham distanc hd hd consid chang tcr repertoir hsct mean hd signific chang transplant v gene famili amino acid chang p p famili strong negat correl hd index tcr repertoir age r result reveal associ hd mean paramet sex diseas condit regimen type transplant data reveal common use condit regimen iran could success caus tcr repertoir divers patient hematolog malign short term amount chang tcr repertoir invers correl increas age patient
|
D018380;D019337
|
T061;T191
|
36,341,565
|
inhibitori effect dutasterid tlr vitro pain studi dutasterid potenti propos control chronic pain toll like receptor tlr inhibit effect tlr express myeloid differenti primari respons myd nuclear factor kappa light chain enhanc activ b cell nf b secretori interleukin il nitric oxid lipopolysaccharid lps stimul u mg cell line human astrocytoma u mg cell line cultur incub gml lps hour creat neuro inflamm model use two differ treatment approach first approach includ lps treatment hour follow dutasterid gml incub next hour second treatment approach cell co incub lps dutasterid hour express tlr myd nf bp secretori il evalu western blot express assess assay tlr myd nf bp secretori il level increas lps treat cell hour dutasterid signific decreas secret also level tlr myd nf bp treatment approach differ il level seen second treatment approach dutasterid anti inflammatori properti probabl analges effect mechan differ convent analges
|
D051197;D008070
|
T109;T116;T192
|
36,341,564
|
molecular characterist bladder tumor increas gene express mage mage decreas microrna microrna b bladder cancer recogn one top ten common cancer worldwid activ oncogen inactiv tumor suppressor gene dysregul androgen signal pathway three major pathophysiolog caus develop bladder tumor discov potenti biomark requir manag immunotherapi bladder cancer melanoma associ antigen mage mage two cancer testi antigen potenti coregul androgen receptor microrna especi mir mir b two import tumor suppressor play critic role regul differ signal pathway inhibit tumor develop twenti nine surgic tissu biopsi collect patient preoper chemotherapi radiotherapi male femal mean agesd year seventeen adjac uninvolv tissu abnorm upon histolog examin consid normal control male femal mean agesd year quantit pcr perform evalu gene express level mage mage mir mir b bladder cancer biopsi mage mage express signific increas bladder tumor compar normal tissu howev express level mir mir b signific downregul bladder tumor tissu interest express level gene signific associ tumor grade patholog stage pt muscular invas mage mage consid potenti marker diagnosi immunotherapi bladder tumor furthermor modul mir mir b gene express associ increas mage mage gene could open new horizon improv bladder cancer
|
D035683;D001749
|
T123;T191;T114
|
36,341,563
|
vitro vivo evid intra tumor inject allogen serum immunotherapi mous model colon cancer believ preform antibodi respons blood transfus reaction transplant reject order remov tumor tissu must reject basi transfus reaction transplant immunolog hypothes allogen serum inhibit tumor growth inject intra tumor initi vitro cytotox test conduct use cbl serum intact decompl combin balbc origin ct cell line ct cell line use establish mous model colon cancer tumor palpabl cbl serum inject intra tumor addit tumor size hypoxia metastat capac angiogenesi metabol inflammatori status evalu matrix metalloproteinas mmp vascular endotheli growth factor vegf cluster design cd cd interleukin il vitro experi show heat inactiv cbl serum signific lower cytotox effect balbc deriv ct cell intact cbl serum balbc serum vivo experi reveal tumor size hif mmp mmp level signific lower experiment group control group contrast control anim allogen serum treatment led mark reduct cd vegf cd il level new approach serum plasma therapi allogen vaccin cancer intra tumor inject allogen serum light eas avail allogen immunotherapi allogen serum plasma therapi could potenti use altern monotherapi combin therapi
|
D003110;D018380
|
T061;T191
|
36,341,562
|
associ gene polymorph cxc chemokin receptor rheumatoid arthriti suscept rheumatoid arthriti ra caus complic interact gene environ cxc chemokin receptor cxcr requir b follicular helper cell migrat humor immun generat therefor studi aim assess whether polymorph cxcr gene implic ra develop progress case control studi enrol ra patient healthi control polymeras chain reaction ligas detect reaction method use genotyp rs rs rs rs cxcr gene epidemiolog clinic laboratori data collect retrospect rs allel associ higher risk ra aor adjust odd ratio confid interv ci howev ra group frequenc rs allel lower aor ci regard rs aggg genotyp carrier signific lower risk ra aa genotyp carrier aor ci ra group found differ genotyp signific associ specif laboratori valu includ rheumatoid factor total bilirubin total cholesterol low densiti lipoprotein cholesterol alkalin phosphatas first report indic cxcr polymorph associ ra suscept find lead rise possibl identifi ra suscept individu base genet marker
|
D020022;D001172
|
T047;T032
|
36,341,561
|
analysi differenti express microrna ova induc airway remodel model mice microrna mirna particip airway remodel regul immun molecul express aim identifi differenti mirna involv airway remodel airway remodel induc ovalbumin femal balbc mice differenti express mirna screen microarray go gene ontolog kegg enrich analysi perform mirna target gene network mirna target pathway network construct verif real time pcr western blot perform identifi differenti express mirna regul regul lung ovalbumin induc airway remodel mice real time pcr confirm mirna mmu mir mmu mir p mmu mir p signific regul mirna mmu mir p mmu mir p mmu mir b p mmu mir b p signific regul mirna target gene network analysi identifi key mrnas airway remodel tnrcb trinucleotid repeat contain adaptor b sesn sestrin baza bromodomain adjac zinc finger domain cux cut like homeobox mirna target pathway network show signal pathway mapk mitogen activ protein kinas pikakt phosphoinositid kinaseprotein kinas b p protein mtor mammalian target rapamycin close relat airway remodel asthma collect differenti mirna involv airway remodel mmu mir mmu mir p mmu mir p mmu mir p mmu mir p mmu mir b p well target gene tnrcb sesn baza cux pathway mapk pikakt p mtor pathway identifi find may help understand pathogenesi airway remodel
|
D051057;D035683
|
T123;T126;T116;T114
|
36,341,560
|
review aspirin exacerb respiratori diseas immunolog efficaci aspirin desensit aspirin exacerb respiratori diseas aerd chronic inflammatori diseas defin asthma chronic rhinosinus nasal polyposi hypersensit reaction aspirin nonsteroid anti inammatori drug aspirin desensit ad confirm effect treatment control aerd inflamm modul immun respons aim review aerd overview epidemiolog pathophysiolog treatment also discuss effect ad immunolog marker involv aerd pathogenesi search electron databas aerd perform includ five random clinic trial rcts ad also search databas recent studi investig effect ad immunolog mechan aerd rcts demonstr therapeut effect ad patient qualiti life asthma symptom score inhal oral steroid use forc expiratori volum sec fev inflammatori mediat clinic benefit ad occur though regul innat adapt immun respons involv pathogenesi aerd addit valuabl effect ad rcts side effect gastrointestin bleed asthma exacerb rash report consid reach optim protocol ad
|
D055963;D012852;D009298;D001249
|
T047
|
36,341,559
|
comprehens overview allergen specif immunotherapi type recombin natur extract allergen diagnosi treatment allergi allergen specif immunotherapi ait involv administ allergen extract use desensit allerg patient herbal allergen extract optimum efficaci fewest side effect still challeng produc overcom limit oral immunotherapi epicutan immunotherapi intralymphat immunotherapi artifici recombin allergen prepar evalu recombin allergen becom popular develop molecular diagnost therapeut besid food drug allergen pollen fungal spore allergen studi base relat clinic studi comprehens overview present latest perspect ait method avail allergen product well discuss challeng opportun treat allerg disord
|
D000485;D006967
|
T129;T046
|
36,341,544
|
associ socioeconom status day risk cardiovascular event total hip arthroplasti registri base studi patient patient receiv total hip arthroplasti tha subsequ increas risk cardiovascular diseas cvd socioeconom status ses effect cvd evalu whether low ses associ higher risk readmiss due cvd tha within day set univers tax support healthcar
|
D019644;D002318
|
T061;T047
|
36,341,514
|
glycaem variabl risk advers cardiovascular event acut coronari syndrom relationship differ glycaem variabl gv index advers cardiovascular outcom well understood studi aim determin whether gv relat occurr advers cardiovascular event patient acut coronari syndrom ac
|
D054058;D006943
|
T033;T047
|
36,341,464
|
characterist clinic trial non small cell lung cancer therapeut vaccin regist clinicaltrialsgov even complet surgic treatment chemotherapi non small cell lung cancer nsclc patient also substanti risk recurr spread trend therapeut cancer vaccin could increas anti tumor immun respons prevent tumor relaps studi aim assess characterist nsclc therapeut vaccin regist clinicaltrialsgov
|
D002289;D008175;D019496
|
T121;T129;T191;T116
|
36,341,463
|
microbi dysbiosi gut drive system autoimmun diseas trillion microb surviv thrive insid human bodi tini creatur crucial develop matur immun system maintain gut immun homeostasi microbi dysbiosi main driver local inflammatori autoimmun diseas coliti inflammatori bowel diseas dysbiosi gut also drive system autoimmun diseas type diabet rheumat arthriti multipl sclerosi gut microb direct interact immun system multipl mechan includ modul host microrna affect gene express post transcript level product microbi metabolit interact cellular receptor tlrs gpcrs interact modul crucial immun function differenti lymphocyt product interleukin control leakag inflammatori molecul gut system circul review compil analyz data gain insight underpin mechan mediat system autoimmun diseas understand gut microb trigger protect system autoimmun diseas crucial tackl diseas diet lifestyl modif develop new microbiom base therapeut prebiot probiot identifi diagnost biomark predict diseas risk observ interven microbi popul chang flare autoimmun respons consid microbiom signatur crucial player system autoimmun diseas might hold promis turn untreat diseas manag prevent one
|
D000069196;D064307;D001327;D019936
|
T032;T007;T028;T047;T001
|
36,341,461
|
biolog screen uniqu drug librari target mrgprx allerg drug reaction drug allergi immunolog mediat drug hypersensit reaction dhr g protein coupl receptor gpcrs common drug target communic extracellular signal initi cellular respons recent evid show gpcr mrgprx major import ige independ pseudo allerg dhrs base suspect interact mani fda approv peptiderg compound mrgprx
|
D018013;D004342
|
T046;T116;T192
|
36,341,460
|
tumor infiltr cdcdtim express lymphocyt epitheli ovarian cancer co express cxcl associ improv surviv reactiv tumor infiltr lymphocyt til immun checkpoint inhibitor co stimul proven effect anti cancer strategi broad rang malign howev epitheli ovarian cancer eoc remain larg refractori current cell target immunotherapeut therefor identif novel immun checkpoint target biomark prognost valu eoc warrant combin multicolor immunofluoresc stain singl cell rna sequenc analysi identifi tim cxcl posit tissu resid memori cdcd posit cell trm popul eoc analysi cohort patient high grade serous eoc reveal tim posit trm signific associ improv patient surviv cxcl posit cd posit cell strong link patient respons anti pd immun checkpoint blockad combinatori tim pd blockad therapi may interest activ anti cancer immun eoc
|
D000072597;D010051
|
T191;T116;T192
|
36,341,459
|
gjb promot pancreat cancer liver metastasi enhanc polar surviv neutrophil connexin membran express protein could assembl hexam transfer metabolit secondari messeng howev role pancreat cancer metastasi remain unknown studi compar gene express pattern primari pancreat cancer patient primari liver metastasi specimen found gap junction protein beta gjb signific increas pancreat ductal adenocarcinoma pdac liver metastasi anim experi verifi gjb deplet suppress hepat metastasi pdac cancer cell gjb express increas neutrophil infiltr mechanist studi reveal gjb form channel pdac tumor cell accumul neutrophil transfer cyclic adenosin monophosph camp cancer neutrophil cell support surviv polar taken togeth data suggest gjb could act potenti therapeut target pdac liver metastasi
|
D010190;D021441;D008113
|
T191
|
36,341,458
|
precis strategi select probiot bacteria treatment intestin bacteri dysfunct diseas abund microbiota resid organ bodi util nutrit form reciproc relationship host composit microbiota chang differ patholog condit particular respons stress digest diseas make microbi composit health host bodi interdepend probiot live microorgan demonstr benefici effect physic health use supplement amelior symptom various digest diseas optim microbi composit gut restor digest balanc howev supplementari effect achiev expect result therefor target screen strategi probiot bacteria crucial owe presenc sever bacteri strain core bacteria work effect maintain microbiolog homeostasi stabil gastrointestin tract core bacteria inherit acquir matern pregnanc deliveri other acquir contact mother fece environ know genera function core bacteria could vital isol select probiot bacteria supplement addit support strain probiot bacteria also need comprehens strategi mine core support bacteria clinic use need use metagenom method estim discern typic differenti strain bacteria anoth import strategi treat dysbiosi henc two factor signific carri target isol select function strain compos result probiot prepar applic research clinic use conclus precis probiot supplement screen abund strain bacteria isol specif probiot strain could rapid establish core microbiota need confer resili particular bacteri dysfunct diseas approach help identifi distinct bacteria use improv supplement therapi
|
D019936;D064307;D007410;D001424
|
T032;T007;T028;T047;T001
|
36,341,457
|
saliva antibodi fingerprint reactiv latent virus mildasymptomat covid uniqu patient myalgic encephalomyelitischron fatigu syndrom myalgic encephalomyelitischron fatigu syndrom mecf chronic diseas consid trigger viral infect major case symptom overlap larg post acut sequela covid long covid impli common pathogenet mechan sar cov infect risk factor sustain latent virus reactiv may account symptom post viral fatigu syndrom aim studi first investig whether patient mecf healthi donor hds differ antibodi respons mildasymptomat sar cov infect second analyz whether covid impos latent virus reactiv cohort
|
D015673;D000086382;D015654;D020077
|
T047;T005;T067
|
36,341,456
|
antibodi product mice requir neither vitamin vitamin receptor vitamin receptor well ligand local various immun tissu cell observ led research hypothes role vitamin immun system howev specif role vitamin immun yet clear delin work report undertaken determin mount antibodi respons alter face vitamin defici signal pathway elimin remov nuclear receptor investig provid direct evid vitamin necessari produc antibodi process paramount optim attack mani foreign organ idea vitamin play signific role immun propos repeat mani year address import idea carri studi mice determin vitamin play signific role antibodi product two anim model util mice deplet vitamin mice devoid vitamin receptor possibl role hypocalcemia result vitamin defici antibodi product determin neither absenc vitamin vitamin receptor hypocalcemia affect abil mice mount antibodi respons antigen challeng thus found evid vitamin normal serum calcium requir major form immun
|
D006996;D014808
|
T047
|
36,341,455
|
dock phosphoinositid kinas mediat two complementari signal pathway cxcr depend b cell migrat naiv b cell use chemokin receptor cxcr enter b cell follicl scan cxcl express icam vcam follicular dendrit cell fdcs presenc antigen cxcl cxcr mediat motil main driven rac guanin exchang factor dock contain bind domain phosphoinositid triphosph pip phospholipid p catalyt subunit class ia phosphoinositid kinas pik contribut cxcr mediat b cell migrat precis interdepend dock p pik famili member process remain incomplet understood combin vitro chemotaxi assay vivo imag examin contribut two factor murin nave b cell migrat cxcl data confirm p main catalyt subunit mediat pik depend migrat downstream cxcr wherea contribut chemotaxi trigger cxcr ccr two chemokin receptor express nave b cell contribut p activ cxcr driven migrat complementari dock pharmacolog genet interfer pathway complet abrog b cell chemotaxi cxcl intravit microscopi control gene defici b cell migrat fdcs confirm lack dock caus profound migrat defect wherea p contribut cell speed direct b cell lack activ p also display defect adhes icam yet migrat impair maintain icam defici fdcs sum data uncov two complementari signal pathway mediat dock p enabl cxcr driven nave b cell examin fdcs
|
D018799;D019869
|
T129;T126;T116
|
36,341,453
|
humor immun transcriptom differ covid inactiv vaccian protein subunit vaccin third booster dose human background sever human health world econom burden caus covid attenu vaccin protect efficaci preval immun escap emerg variant concern voc third dose booster immun put agenda system biolog approach help us gain new perspect character immun respons identif factor under vaccin induc immun efficaci analyz antibodi signatur transcript respons particip vaccin covid inactiv vaccin protein subunit vaccin third booster dose result antibodi indic third booster dose effect heterolog vaccin protein subunit vaccin booster dose induc stronger humor immun respons homolog vaccin inactiv vaccin might effect voc transcriptom analysi protein subunit vaccin induc differenti express gene signific associ mani import innat immun pathway homolog heterolog booster could increas effect covid compar inactiv vaccin protein subunit vaccin mediat stronger humor immun respons signific correl innat immun function modul provid certain data support third booster immun strategi
|
D056724;D000086382
|
T047;T040;T067;T043
|
36,341,452
|
meta analysi indic regul cell motil non intrins function chemoattract receptor govern independ direct sens chemoattract defin migrat cell toward sourc chemic gradient control chemoattract receptor chemoattract involv two basic activ name direct sens molecular mechan detect direct sourc chemoattract actin base motil allow migrat cell toward current model assum first chemoattract receptor govern direct sens motil common induc increas migratori speed cell ie chemokinesi second signal pathway control activ intertwin perform meta analysi reassess two point studi emerg two main find first although mani chemoattract receptor govern direct sens also receptor regul cell motil suggest abil control direct sens motil best defin chemoattract receptor second multipl experiment data suggest receptor control direct sens motil control independ hypothes independ may base exist separ signal modul select govern direct sens motil chemotact cell togeth inform gather use updat current model repres signal chemoattract receptor new model may facilit develop strategi effect pharmacolog modul chemoattract receptor control chemoattract health diseas
|
D044042;D002633
|
T043;T116;T038;T192
|
36,341,451
|
evalu porcin gm csf prrsv infect vitro vivo indic protect role gm csf relat bias activ alveolar macrophag prrsv infect granulocyt macrophag coloni stimul factor gm csf particip divers biolog process associ innat adapt immun unknown effect prrsv infect doubl antibodi sandwich elisa pgm csf develop hous evalu pgm csf level prrsv infect vitro vivo vitro assay notabl prrsv infect porcin alveolar macrophag pam yield inconsist pgm csf protein mrna level suggest post transcript inhibit pgm csf mrna employ prrsv meanwhil concurr analysi pgm csf level serum sampl prrsv infect piglet suggest effect prrsv infect demonstr minimum effect pgm csf level regardless prrsv virul phenotyp moreov vitro treatment pam pgm csf prior prrsv inocul inhibit prrsv replic pam although gene downstream pgm csf pam could upregul pgm csf treatment meanwhil knockdown pgm csf use sirna enhanc prrsv replic well intrigu therapeut antibodi treatment hp prrsv infect piglet led signific increas serum pgm csf level thus align low pneumonia incid low intracellular prrsv rna level pam therapeut antibodi treat piglet furthermor transcriptom analysi pam infect piglet reveal increas serum pgm csf level correl activ downstream signal pgm csf pam evidenc like phenotyp gene express pattern impli potenti host protect role play pgm csf prrsv infect vivo conclus result demonstr develop high sensit specif elisa pgm csf reveal potenti protect role confer pgm csf prrsv infect
|
D019316
|
T005
|
36,341,450
|
advers event immun checkpoint inhibitor patient digest system cancer systemat review meta analysi studi incid distribut advers event immun checkpoint inhibitor ici digest system cancer provid refer safe ration effect use immun detect site inhibitor
|
D064420;D004067
|
T046;T191;T037
|
36,341,449
|
archetyp type ii iii toxoplasma gondii oocyst induc differ immun respons clinic outcom experiment infect piglet livestock anim swine import sourc toxoplasma gondii human popul current limit knowledg regard potenti influenc gondii genotyp might exert establish infect swine herein investig role gondii isol type ii iii repres genotyp circul europ immun respons infect dynam piglet recent obtain oocyst gondii field isol tgshsp type ii toxodb genotyp tgshsp type iii use oral infect thirteen day old femal piglet landrac larg white crossbre random alloc three differ group group g n inocul tgshsp group g n inocul tgshsp group g n non infect control group clinic sign monitor daili day post infect dpi piglet euthan blood sampl collect week test cellular immun respons parasit stimul peripher blood specif igg igg igg respons sera parasit distribut burden evalu target tissu use mous bioassay quantit rt pcr qpcr apathi moder decreas feed consumpt observ g g piglet dpi coincid fever gt c g piglet higher temperatur longer durat use mous bioassay qpcr detect frequenc higher g vs g highest parasit burden target tissu also found g seroconvers detect dpi infect group higher antibodi level observ g piglet cytokin analys reveal product il il ifn dpi infect group moreov il produc dpi g dpi g level il higher g il il ifn higher g dpi cytokin profil reveal predomin proinflammatori respons could involv limit gondii infect piglet although effici tgshsp type ii driven infect
|
D014122;D014124
|
T047;T204
|
36,341,448
|
tcr bind predictor fail general unseen peptid sever recent studi investig tcr peptid pmhc bind predict use machin learn deep learn approach mani method achiev impress result test set includ peptid sequenc also includ train set work investig state art deep learn model tcr peptid pmhc bind predict general unseen peptid creat dataset includ posit sampl iedb vdjdb mcpas tcr mira set well negat sampl random x genom assay name collect sampl tchard propos hard split simpl heurist trainingtest split ensur test sampl exclus present peptid belong train set investig effect differ trainingtest split techniqu model test perform well effect train test model use mismatch negat sampl generat random addit negat sampl deriv assay result show modern deep learn method fail general unseen peptid provid explan happen verifi hypothesi tchard dataset conclud robust predict tcr recognit still far solv
|
D011948;D010455
|
T129;T121;T116;T192
|
36,341,447
|
age envisag imbal periodontium keyston oral diseas system health age gradual progress deterior integr across multipl organ system negat affect gingiv wound heal cellular respons associ wound heal collagen synthesi cell migrat prolifer collagen contract shown lower gingiv fibroblast abund cell connect gingiv tissu age donor young donor cellular senesc one hallmark age character acquisit senesc associ secretori phenotyp character releas pro inflammatori cytokin chemokin growth factor proteas implic recruit immun cell neutrophil cell monocyt moreov age macrophag show alter acquisit function phenotyp respons tissu microenviron thus inflammatori resolut macrophag mediat process impair impact progress periodont diseas interest salivari antimicrobi peptid histatin involv various function antifung bactericid enamel protect angiogenesi epithel shown fluctuat age sever studi associ presenc porphyromona gingivali key pathogen relat periodont apic periodont progress alzheim diseas well gut esophag gastric cancer moreov herp simplex virus type associ sever periodont diseas cardiovascular complic nervous system relat patholog review encompass effect age periodont tissu p gingivali hsv infect could favor periodont relationship patholog
|
D010518;D010510
|
T047
|
36,341,446
|
ilra singl nucleotid polymorph associ size function mait cell popul treat hiv infect mait cell persist deplet function exhaust hiv infect patient despit long term combin antiretrovir therapi cart il treatment support mait cell reconstitut vivo hiv infect individu rescu function vitro singl nucleotid polymorph snps il ra gene modul level solubl il r scd level influenc bioavail circul il evalu potenti influenc il ra polymorph mait cell number function healthi control hc subject hiv infect individu long term cart find indic il ra haplotyp h defin allel carrier tag snp rs affect size peripher blood mait cell pool well product cytokin cytolyt effector protein respons bacteri stimul h carrier lower sil r level higher mait cell frequenc enhanc function link higher express mait cell associ transcript factor despit averag year suppress cart mait cell level function hiv infect individu still signific lower hc notabl observ signific correl mait cell level cart durat hiv infect individu carri il ra haplotyp interest treatment sil r vitro suppress il depend mait cell prolifer function follow cognat stimul observ suggest sil r level may influenc mait cell number function vivo limit il bioavail mait cell collect observ suggest il ra polymorph may play signific role mait cell biolog influenc mait cell recoveri hiv infect potenti link ilra polymorph mait cell immunobiolog hiv infect warrant studi go forward
|
D015497;D000072336;D015658
|
T005;T025;T047
|
36,341,445
|
immun defens mammari gland epithelium dairi rumin epithelium mammari gland mg fulfil three major function nutrit progeni transfer immun mother newborn defens infect defens function epithelium requir cooper mammari epitheli cell mec intraepitheli leucocyt macrophag dcs resid lymphocyt mg character secret larg amount nutrient liquid certain bacteria prolifer reach consider bacteri load condit udder react bacteri invas review present mammari epithelium perceiv bacteria respond main bacteri genera associ mastiti mec abl detect presenc activ multipli bacteria lumen gland express pattern recognit receptor prrs recogn microb associ molecular pattern mamp releas grow bacteria interact intraepitheli leucocyt fine tune mec respons follow onset inflamm new interact establish lymphocyt neutrophil recruit blood mammari epithelium also identifi respond antigen suppos antigen present capac respons manipul drug plant extract probiot immun modifi order increas defens capac reduc damag relat inflamm numer studi establish mammari epithelium genuin effector innat adapt immun howev knowledg gap remain newli avail tool offer prospect excit research unravel exploit multipl capac particular epithelium
|
D008321;D008414
|
T023;T047
|
36,341,444
|
lymphat system covid vaccin understand precis mechan vaccin induc protect immun correl protect coronavirus diseas covid crucial import develop next generat vaccin confer durabl protect immun covid similar factor also import infecti diseas briefli summar mechan action current use covid mrna vaccin viewpoint function lymphat system
|
D000086382;D014765
|
T129;T047;T121;T067
|
36,341,443
|
case report et gene delet associ low number recent thymic emigr three patient jacobsen syndrom jacobsen syndrom rare genet disord associ termin delet chromosom clinic present variabl although immunodefici describ patient jacobsen syndrom clear genotyp phenotyp correl yet establish report immunolog phenotyp four patient jacobsen syndrom four patient show one atyp immunolog featur one patient suffer recurr viral infect two patient experienc sever bacteri infect one receiv antibiot prophylaxi sinc earli childhood one patient experienc sever transient immun dysregul hypogammaglobulinemia low b cell count found two patient number recent thymic emigr cdcdra cd cell abnorm low three consid six immun relat gene locat within affect part chromosom et tirap fli nfrkb thyn snx et gene found delet three patient low number recent thymic emigr non switch memori b cell find support hypothesi wherebi jacobsen syndrom associ combin immunodefici variabl present investig potenti genotyp phenotyp correl warrant might help person patient manag individu lack immun relat gene addit recommend immunolog follow patient jacobsen syndrom immun abnorm may develop time
|
D054868
|
T047
|
36,341,442
|
il critic chronic heart dysfunct mice chaga diseas long trypanosoma cruzi infect individu develop progress chronic chagas cardiomyopathi ccc systol dysfunct arrhythmia sinc previous show il mediat develop systol dysfunct cardiac arrhythmia diabet mellitus cardioren syndrom il remain elev chaga diseas patient test role il ccc use mous model mice defici il r express il r surviv acut cruzi infect greater parasitemia control lose weight wild type wt chronic stage wt present prolong ventricular repolar interv qj il r present interv like noninfect control infect il r wt differ stroke volum sv incid cardiac arrhythmia electrocardiographi ekg whole heart action potenti durat apd incid trigger activ protocol measur suscept cardiac arrhythmia also treat chronic infect wt mice il r antagonist anakinra treatment shorten qj interv improv sv incid cardiac arrhythmia ekg anakinra fail reduc trigger activ follow electr extra stimul protocol conclus absenc function il il r signal prevent revers decreas sv incid cardiac arrhythmia induc chronic cruzi infect impli critic mechan generat maintain ccc sinc similar cardiac abnorm previous credit il signal rule mechan import discourag attempt il blockad therapeut measur
|
D014349;D014355;D009202
|
T047;T204
|
36,341,441
|
benefici effect lacticaseibacillus casei small intestin colon swiss mice deleteri effect fluorouracil intestin mucos one common import side effect fluorouracil fu current still specif effect protocol prevent treatment aim present studi evalu effect oral administr lacticaseibacillus casei l casei progress fu induc intestin mucos method l casei x cfuml salin oral administ swiss mice begin day intestin mucos induct singl intraperiton fu administr mgkg bodi weight number peripher leukocyt fecal lactic acid bacteria monitor euthanasia day tissu sampl colon small intestin segment collect histopatholog jejun tissu collect evalu ino tnf alpha immunoexpress il beta il tnf alpha level malonaldehyd mda accumul invertas activ factor nuclear kappa b nfkb p gene express toll like receptor tlr mucin muc occludin zonula occluden zo
|
D052016;D007780
|
T046;T007
|
36,341,440
|
advanc car cell therapi bile duct pancreat gastric cancer bile duct pancreat gastric cancer dead digest system tumor high malign poor patient prognosi effici convent surgic treatment radiat therapi chemotherapi limit contrast chimer antigen receptor car cell therapi repres landmark therapeut approach antitumor immun great efficaci treat sever hematolog malign car cell therapi involv genet engin express specif antibodi base patient cell surfac amplifi antibodi identifi target tumor associ antigen car cell therapi effect inhibit diseas progress improv surviv patient bile duct pancreat gastric cancer effect car cell tumor therapi valid use xenograft model provid scientif test platform studi review progress car cell product develop focus current status optim strategi engin car cell bile duct pancreat gastric cancer
|
D016219;D013274
|
T061;T191
|
36,341,439
|
prime shock kill bcl inhibit hiv cure modern hiv therapi effect suppress viral replic persist latent reservoir posit greatest hurdl complet cure shock kill strategi investig hiv therapi aim reactiv latent hiv subsequ elimin anti retrovir therapi host immun function howev thus far studi yield suboptim result stem combin ineffect latenc revers poor immun clearanc concomit studi reveal import bcl anti apoptot protein critic mediat infect cell surviv reservoir mainten immun evas hiv furthermor bcl inhibitor recogn anti hiv effect pre clinic studi minireview aim examin intersect bcl inhibit current shock kill effort hope inform futur studi may ultim yield cure hiv
|
D015497;D015658
|
T005;T047
|
36,341,438
|
identif serum glycobiomark hepatocellular carcinoma use lectin microarray hepatocellular carcinoma hcc sixth common occur cancer rank third mortal among malign tumor result hcc repres major human health issu although aberr glycosyl clear implic hcc chang serum immunoglobulin ig g igm glycosyl comprehens character studi use lectin microarray evalu differ serum igg igm glycosyl among patient hcc hepat b cirrhosi hbc chronic hepat b chb healthi normal control nc aim establish model improv diagnost accuraci hcc
|
D006528;D008113;D006509
|
T047;T191
|
36,341,437
|
role cuproptosi relat gene classif prognosi melanoma melanoma one aggress malign cancer rank first lethal rate skin cancer cuproptosi shown pali role tumorigenesi howev role cuproptosi melanoma metastasi clear studi correl beteen molecular subtyp cuproptosi relat gene crgs metastasi melanoma may provid guidanc prognosi melanoma
|
D008545;D012878
|
T191
|
36,341,436
|
amino acid metabol base molecular classif colon adenocarcinomavia silico analysi amino acid metabol close relat occurr develop colon adenocarcinoma coad studi relationship coad express amino acid metabol still rare base silico analysi use amino acid metabol relat gene aamrg determin amino acid metabol characterist classifi coad two distinct subtyp name aa aa analyz clinic characterist somat mutat landscap transcriptom profil metabol signatur immun infiltr therapi sensit two subtyp aa subtyp inferior overal surviv character lower amino acid metabol activ higher tumor mutat burden higher immun cell infiltr aa display higher metabol activ relat better surviv furthermor aa subtyp like benefit irinotecan chemotherapi immun checkpoint blockad therapi includ program cell death protein pd cytotox lymphocyt associ protein ctla immun checkpoint inhibitor resist target therapi cetuximab aa subtyp show higher sensit fluorouracil oxaliplatin provid perspect cell specif metabol investig explor metabol activ differ cell type includ lymphocyt mast cell myeloid cell stromal cell epitheli cell via colorect cancer singl cell data addit assist clinic decis make prognosi predict aamrg base classifi generat valid independ cohort
|
D000230;D003110
|
T191
|
36,341,435
|
novel twelv gene signatur predict neoadjuv chemotherapi respons prognosi breast cancer accur evalu respons neoadjuv chemotherapi nac provid import inform system therapi breast cancer impli pharmacolog respons prognosi guid therapi gene profil overcom shortcom relat limit detect indic classic patholog evalu criteria subject observ complic expens therefor essenti develop accur repeat econom evalu approach neoadjuv chemotherapi respons
|
D020360;D001943
|
T061;T191
|
36,341,434
|
metabol reprogram sar cov infect impact outcom covid patient sever acut respiratori syndrom coronavirus sar cov infect trigger inflammatori clinic stage affect outcom patient coronavirus diseas covid diseas sever may associ metabol imbal relat amino acid lipid energi generat pathway aim studi character profil amino acid acylcarnitin covid patient multicent cross section studi carri total individu classifi diseas sever level amino acid acylcarnitin succinylaceton serum sampl analyz electrospray ionize tripl quadrupol tandem mass spectrometri differ cluster observ partial least squar discrimin analysi phenylalanin alanin citrullin prolin succinylaceton provid major contribut variabl cluster variabl import project gt logist model adjust age sex type diabet mellitus hypertens nutrit status phenylalanin associ critic outcom odd ratio ci sever vs critic model area curv ci conclus metabol imbal covid patient might affect diseas progress work show associ phenylalanin critic outcom covid patient highlight phenylalanin potenti metabol biomark diseas sever
|
D000086382;D003924
|
T047;T067
|
36,341,433
|
complement target therapeut ischemia reperfus injuri transplant potenti ex vivo deliveri organ shortag expand waitlist led increas util margin organ donor organ subject vari degre iri transplant process extend criteria organ includ older donor organ donat circulatori death especi vulner ischemia reperfus injuri iri involv complement cascad mediat iri studi extens complement play vital role propag iri subsequ recruit adapt immun element complement inhibit various point pathway shown mitig iri minim futur immun mediat injuri preclin model recent introduct ex vivo machin perfus platform provid ideal window therapeut intervent review role complement iri organ system highlight potenti therapeut target intervent ex vivo machin preserv donor organ
|
D015427;D016030
|
T061;T037
|
36,341,432
|
antibodi base condit allogen hematopoiet stem cell transplant allogen hematopoiet stem cell transplant allo hsct curat therapeut option mani patient hematolog malign nonmalign hematopoiet disord achiev stabl engraft donor hematopoiet stem cell hscs recipi hsc delet need creat space incom donor hscs donor hscs must escap immun reject recipi convent allo hsct requir high dose irradi andor chemotherapi produc suffici host stem cell immun system ablat permit donor hsc engraft howev procedur also result nonspecif tissu injuri caus short long term advers effect well incit amplifi graft versus host diseas gvhd deliveri target radiotherapi hematopoiet tissu use radioimmunoconjug roic part transplant prepar regimen shown clinic benefit roic clinic data provid evid decreas relaps without increas transplant relat mortal deliv higher target radiat site malign given nontarget fashion altern approach allo hsct develop test preclin mous model nonmyeloabl precondit low dose alkyl agent busulfan lower system dose irradi combin co stimulatori pathway blockad ctla ig anti cdl monoclon antibodi andor immunosuppress drug use condit mix chimer transplant toler fulli mhc mismatch donor marrow observ recent sever novel proof concept antibodi mediat precondit method develop select target hematopoiet stem immun cell minim overal toxic antibodi drug conjug adc combin reduc intens condit high dose adc singl dose monotherapi shown promis allo hsct preclin model purpos current review discuss literatur explor antibodi base condit includ nativ antibodi radiolabel antibodi conjug adc allo hsct
|
D018380;D006086;D019337
|
T061;T047;T191
|
36,341,431
|
updat role complement hepatocellular carcinoma main produc complement environ liver great affect complement system although complement system consid abil nonself discrimin remark studi reveal tight associ improp complement activ tumour initi progress complement activ predomin occur within liver protumourigen role complement system may contribut develop hepatocellular carcinoma hcc improv understand molecular target involv complement mediat tumour develop metastasi tumour promot inflamm hcc would certain aid develop better treatment minireview focus recent find protumourigen role complement system hcc
|
D006528;D008113
|
T191
|
36,341,430
|
feasibl avian antibodi prophylaxi enterotoxigen escherichia coli colon research aim evalu feasibl use avian immunoglobulin igi rais adhes factor enterotoxigen escherichia coli etec prophylaxi diarrheal ill caus pathogen etec requir adhes human intestin epitheli cell primari step establish enter infect therefor inhibit adhes may prevent infect reduc clinic burden diarrheal ill
|
D054307;D004927
|
T047;T007
|
36,341,428
|
manag tme improv efficaci cancer therapi tumor microenviron tme influenc tumor growth metastat spread respons treatment often immunosuppress mediat tme impair benefici respons complex tumor composit challeng abil design new effect therapi go forward need manag content function tme improv treatment outcom current sever differ kind treatment avail patient cancer tradit approach chemotherapi radiat surgeri target agent inhibit kinas associ oncogen pathway monoclon antibodi target surfac antigen often deliv toxic payload cell final antibodi biolog seek overcom immunosuppress caus element within tme therapi interact tme current intens widespread investig review describ tme immunosuppress compon influenc tumor progress respons treatment focus three particular tumor type classic hodgkin lymphoma chl pancreat ductal adenocarcinoma pdac glioblastoma multiform gbm final offer five approach manipul manag tme improv outcom cancer patient
|
D010190;D021441;D000074322
|
T121;T129;T191;T116
|
36,341,427
|
associ smoke status non small cell lung cancer patient harbor uncommon epiderm growth factor receptor mutat uncommon epiderm growth factor receptor egfr mutat includ singl complex mutat howev associ smoke status patient uncommon complex egfr mutat remain unclear
|
D002289;D008175
|
T191
|
36,341,426
|
role metabol reprogram pro inflammatori cytokin secret lps silica activ macrophag lung macrophag constitut first line defens pathogen foreign bodi play fundament role maintain tissu homeostasi activ macrophag show alter immunometabol metabol chang govern immun effector mechan cytokin secret character classic altern activ lipopolysaccharid lps stimul macrophag demonstr enhanc glycolysi block succin dehydrogenas sdh increas secret interleukin beta il tumor necrosi factor alpha tnf glycolysi suppress use deoxyglucos lps stimul macrophag inhibit il secret tnf indic metabol pathway specif determin cytokin product contrast lps natur immunometabol respons induc non organ particl silica macrophag contribut cytokin specif diseas pathogenesi well understood silica stimul macrophag activ pattern recognit receptor prrs nlrp inflammasom releas il tnf interferon key mediat silicosi pathogenesi contrast bacteria silica particl degrad persist macrophag activ result increas nadph oxidas phox activ mitochondri reactiv oxygen speci ros product ultim lead macrophag death releas silica particl perpetu inflamm manuscript review effect silica macrophag mitochondri respir central carbon metabol determin cytokin specif respons sustain inflammatori respons lung
|
D008070;D012822
|
T197;T109
|
36,341,425
|
humor cellular immun respons coronavac one year vaccin coronavac wide use sar cov inactiv vaccin long term immun respons assess still lack evalu sar cov specif immun respons includ cell activ marker antigen specif cytokin product antibodi respons follow vaccin adult elder individu particip phase clinic trial activ follicular helper tfh non tfh memori cd cell detect almost subject earli first vaccin dose activ memori cd cell predomin central effector memori cell phenotyp sustain least month also detect balanc th th thth type cytokin product associ respons time togeth particular cytokin profil link poor respons older vaccine sar cov specif igg level peak day second dose most stabl one year coronavac abl induc potent durabl antivir antigen specif cellular respons cytokin profil relat respons time impact senesc defin
|
D000086382;D000086663
|
T200;T047;T067
|
36,341,424
|
mine immunolog prognost relat biomark cervic cancer base immun cell signatur immunotherapi chang therapeut landscap cervic cancer cc durabl anti tumor activ subset patient studi aim comprehens analyz tumor immun microenviron time cc mine biomark relat immunotherapi prognosi
|
D002583
|
T191
|
36,341,423
|
immun cell transcriptom base drug reposit multipl sclerosi find target gene target pathway exist drug drug reposit multipl sclerosi ms base transcriptom chang ms immun cell
|
D059467;D009103
|
T081;T047;T086
|
36,341,422
|
role periostin inflammatori bowel diseas develop synergist effect mediat ccl ccr axi inflammatori bowel diseas ibd compris main crohn diseas cd ulcer coliti uc chronic inflammatori diseas gastrointestin tract recent year wealth data accumul demonstr complex interplay mani differ factor pathogenesi ibd among factor impact epitheli barrier function includ vessel extracellular matrix ecm format gut microbiom eg bacteri antigen import product cytokin pro anti inflammatori direct shape immun respons patient fail resolv acut intestin inflamm develop chronic inflamm shown express matricellular protein periostin enhanc ibd one driver diseas c c chemokin receptor ccr engag chemotact mediat cclmip cclmip cclrant ccr blockad report amelior inflamm murin ibd model thus periostin ccr involv develop ibd studi investig potenti crosstalk two signal system test high potent ccl deriv act ccr antagonist murin model ibd observ absenc periostin influenc ccr express cell popul gut data support notion target modul periostin ccr signal system bear therapeut potenti ibd
|
D019707;D015212
|
T129;T047;T116;T192
|
36,341,421
|
conserv oxygen therapi critic ill periop period patient sepsi associ encephalopathi sepsi associ encephalopathi sae patient intens care unit icu periop period administr supplement oxygen howev correl oxygen status sae target oxygen therapi remain unclear studi aim examin relationship oxygen therapi sae patient
|
D065166
|
T047;T048
|
36,341,420
|
rheumatoid factor igm autoantibodi control igg homeostasi rheumatoid arthriti autoimmun diseas character joint inflamm due autoantibodi target multipl self protein patient poor prognosi show elev titer igm antibodi specif bind igg autoreact antibodi refer rheumatoid factor rf howev biolog function contribut diseas progress remain elus recent shown autoreact antibodi present healthi individu play import role regul physiolog process regulatori mechan determin class affin autoreact antibodi low affin autoreact igm neutral recogn autoantigen high affin igm protect autoantigen degrad show rfs possess high affin mono specif igg stabil effect igg wherea low affin polyreact rfs neutral igg vivo result suggest autoreact igm antibodi recogn igg play crucial role regul igg homeostasi disbal igm mediat igg degrad stabil might affect onset progress autoimmun diseas consequ restor balanc use low affin anti igg igm might promis therapeut approach autoimmun diseas involv autoreact igg
|
D012217;D001172
|
T129;T047;T116
|
36,341,419
|
incid factor associ cutan immun relat advers event immun check point inhibitor ambispect cohort studi although immun checkpoint inhibitor ici becom frontlin treatment option patient various advanc cancer due improv surviv associ spectrum cutan immun relat advers event cira howev littl known regard occurr pattern cira relat ici therapi patient differ race white popul therefor investig incid associ factor cira among cancer patient northern thailand
|
D000074322;D008175;D007154
|
T129;T121;T116;T191;T047
|
36,341,418
|
helicobact pylori infect human neutrophil exhibit impair chemotaxi uropod retract defect helicobact pylori major human pathogen colon gastric mucosa play causat role develop peptic ulcer gastric cancer neutrophil heavili infect organ vivo play promin role tissu destruct diseas recent demonstr h pylori exploit neutrophil plastic part virul strategi elicit n like subtyp differenti notabl profound nuclear hypersegment undertook studi test hypothesi hypersegment may enhanc neutrophil migratori capac howev ez taxiscan video imag reveal previous unappreci progress chemotaxi defect appar prior hypersegment onset cell speed direct signific impair fmlf well ca il infect cell orient normal chemotact gradient speed direct impair uropod retract defect led cell elong nuclear lobe trap contract rear progress narrow lead edg contrast chemotact receptor abund adhes phagocytosi aspect cell function unchang molecular level h pylori phenocopi effect blebbistatin indic aberr accumul f actin actin spike uropod togeth enhanc rockii mediat phosphoryl myosin iia regulatori light chain time rhoa rockii disappear cell rear accumul lead edg wherea myosin iia enrich cell pole data suggest h pylori inhibit dynam chang myosin iia contractil front back polar essenti chemotaxi taken togeth data advanc understand pmn plastic h pylori pathogenesi
|
D016480;D024507;D007960
|
T047;T007;T126;T116
|
36,341,417
|
gain function trpm predispos mice psoriasiform dermat transient receptor potenti melastatin trpm ca activ monoval cation channel express wide rang cell previous report two gain function gof mutat trpm caus progress symmetr erythrokeratodermia psek share similar clinic histopatholog featur psoriasi use crisprca technolog generat trpmim mice equival mutat one two genet mutat found human psek equival human trpmim use mutant mice examin effect trpm gof cellular phenotyp level elucid patholog mechan under psek absenc experiment stimul trpmim mice show phenotyp treat imiquimod imq howev trpmim mice predispos sever psoriasiform dermat psd wild type wt character greater accumul ccr express cell higher mrna level ila trpmim mice dendrit cell show enhanc migrat keratinocyt exhibit increas prolifer moreov trpm inhibitor glibenclamid amelior psd wt trpmim mice result indic elev trpm activ boost suscept cutan stimuli like elev membran potenti alter downstream cellular signal result enhanc inflamm result suggest possibl therapeut applic trpm inhibitor psoriasi
|
D011565;D004485;D050053
|
T123;T047;T116
|
36,341,416
|
hallucin structur condit antibodi librari target specif binder antibodi wide develop use therapeut treat cancer infecti diseas inflamm develop initi lead routin undergo addit engin increas target affin experiment method affin matur expens labori time consum rare allow effici explor relev design space deep learn dl model transform field protein engin design sever dl base protein design method shown promis antibodi design problem distinct special model antibodi design desir inspir hallucin framework leverag accur structur predict dl model propos fvhallucin design antibodi sequenc especi cdr loop condit antibodi structur strategi generat target cdr librari retain conform binder therebi mode bind epitop antigen benchmark set antibodi fvhallucin generat sequenc resembl natur cdrs recapitul perplex canon cdr cluster furthermor fvhallucin design amino acid substitut vh vl interfac enrich human antibodi repertoir therapeut antibodi propos pipelin screen fvhallucin design obtain librari enrich binder antigen interest appli pipelin cdr h trastuzumab complex generat silico design predict improv upon bind affin interfaci properti origin antibodi thus fvhallucin pipelin enabl generat inexpens divers target antibodi librari enrich binder antibodi affin matur
|
D022801;D000906
|
T129;T121;T116
|
36,341,415
|
target deliveri liposom chemoimmunotherapi cancer treatment chemoimmunotherapi util immunomodulatori effect chemotherapeut shown great promis treat poor immunogen solid tumor howev remain signific room improv synergi chemotherapi immunotherapi includ effici concurr deliveri chemotherapeut immunomodul tumor report use metabol glycan label facilit cancer target deliveri liposom chemoimmunotherapi tripl negat breast cancer cell metabol label azido group subsequ target conjug dibenzocycoloctyn dbco bear liposom load doxorubicin imiquimod r adjuv via effici click chemistri encas doxorubicin induc immunogen death cancer cell upregul express cd calreticulin surfac cancer cell r activ dendrit cell enhanc process present tumor antigen target deliveri liposom encapsul doxorubicin r tumor enabl metabol glycan label click chemistri show promis reshap immunosuppress tumor microenviron solid tumor cancer target liposom chemoimmunotherapi could provid new approach improv convent chemotherapi
|
D008081;D009369
|
T191;T109
|
36,341,414
|
rectal mucos immun environ hiv suscept among young men sex men young men sex men ymsm repres particular high risk group hiv acquisit us despit similar report rate sexual activ older adult msm amsm increas rate hiv infect among ymsm compar amsm could partial attribut differ within rectal mucos rm immun environ associ earlier sexual debut less lifetim exposur recept anal intercours use ex vivo explant hiv challeng model found rectal tissu ymsm support higher level p peak viral replic timepoint compar amsm among ymsm rm character increas cd cell prolifer well lower frequenc tissu resid cd cell pro inflammatori cytokin produc cd cd cell addit microbiom composit ymsm enrich anaerob taxa previous associ hiv acquisit risk includ prevotella peptostreptococcus peptoniphilus distinct immunolog microbiom characterist found associ higher hiv replic follow ex vivo challeng rectal explant suggest rm microenviron ymsm may uniqu conduc hiv infect
|
D015658;D000072339
|
T047;T098
|
36,341,413
|
tidi unfold protein respons sepsi pathogen toxic byproduct subsequ immun reaction exert differ form stress damag tissu infect host stress trigger specif transcript post transcript program evolv limit pathogenesi infecti diseas confer tissu damag control program fail infecti diseas take sever cours includ organ dysfunct damag phenomenon known sepsi associ high mortal one key adapt mechan counter infect associ stress unfold protein respons upr aim reduc endoplasm reticulum stress restor protein homeostasi mediat via set divers complementari mechan ie reduct protein translat increas protein fold capac increas polyubiquitin misfold protein subsequ proteasom degrad howev upr exclus benefici sinc enhanc prolong activ might lead detriment effect cell death thus fine tune time restrict regul upr diminish diseas sever infecti diseas improv outcom sepsi bear long term consequ review describ current knowledg upr role infecti diseas regul mechan clinic implic sepsi
|
D018805;D003141
|
T047;T046
|
36,341,412
|
common molecular mechan immun infiltr pattern thorac abdomin aortic aneurysm aortic diseas aortic aneurysm aa dissect ad serious threat patient live littl current known molecular mechan immun infiltr pattern under develop progress thorac abdomin aortic aneurysm taa aaa warrant research
|
D017544;D017545
|
T047
|
36,341,411
|
solut carrier nutrient transport rheumatoid arthriti fibroblast like synoviocyt metabolom studi show rheumatoid arthriti ra associ metabol disrupt metabol chang fibroblast like synoviocyt fls like contribut fls abnorm respons strong contribut joint destruct chang often involv increas express nutrient transport meet high demand energi biomolecul solut carrier slc transport famili nutrient transport serv metabol gate cell mediat transport sever differ nutrient glucos amino acid vitamin neurotransmitt inorganicmet ion ra fls slc mediat transmembran transport one pathway associ differ epigenet landscap ra osteoarthr oa fls highlight transport slc famili offer uniqu target research offer promis futur therapeut target ra
|
D000070918;D001172;D010003
|
T047;T025
|
36,341,410
|
prognost valu hematolog paramet advanc non small cell lung cancer patient receiv anti pd inhibitor associ hematolog paramet anti program death pd inhibitor general examin without consid therapi line medicin type studi aim identifi potenti hematolog biomark associ clinic outcom patient non small cell lung cancer nsclc treat first line pembrolizumab subsequ line nivolumab
|
D002289;D008175;D000074322
|
T121;T129;T191;T116
|
36,341,409
|
abrog neutrophil inflammatori pathway potenti reduct neutrophil relat factor covid intraven immunoglobulin pathogenesi lung injuri covid complet understood leav gap understand current treatment modul cours covid neutrophil number activ state circul found correl covid sever neutrophil extracellular trap net found lung parenchyma patient acut respiratori distress syndrom ard covid target pro inflammatori function neutrophil may diminish lung injuri covid ard neutrophil isol peripher blood healthi donor treat ex vivo dexamethason tocilizumab intraven immunoglobulin ivig net format oxid burst phagocytosi assess plasma critic ill covid patient clinic treatment ivig healthi donor assess neutrophil activ relat protein dexamethason tocilizumab affect pma nigericin induc net product ex vivo ivig induc dose depend abrog net product activ model ivig also reduc pma elicit reactiv oxygen speci product alter phagocytosi covid patient found elev level cell free dna neutrophil elastas il compar healthi control level cell free dna neutrophil elastas lower day day daili treatment ivig lack impact dexamethason tocilizumab neutrophil function suggest therapeut agent may act suppress neutrophil function indic door might still open addit neutrophil modul covid therapeut repertoir
|
D000086382;D055370;D012128;D000073888
|
T123;T067;T037;T114;T047
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.